Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.
Rauova
L
L
Center for Autoimmune Diseases, Tel Hashomer, Israel.
Rovensky
J
J
Shoenfeld
Y
Y
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000918:Antibody Specificity; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000096:biosynthesis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000276:immunology; D007074:Immunoglobulin G / Q000378:metabolism; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets / Q000276:immunology; D051379:Mice; D018345:Mice, Knockout; D010920:Placenta / Q000276:immunology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016207:Cytokines; D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D007130:Immunoglobulin Idiotypes; D016756:Immunoglobulins, Intravenous